Overall, 10% of patients with NSCLC in the United States and 35% in Asia have tumor-associated epidermal growth factor receptors (EGFR) mutations, which are predictive of response to EGFR-tyrosine kinase inhibitors (TKIs) [154]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.